Loading clinical trials...
Loading clinical trials...
The purpose of the survey is to evaluate the safety and efficacy of Irribow and Irribow OD Tablets in post-marketing medical practice and to examine the status of treatment compliance.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Astellas Pharma Inc
NCT06737666 · Diarrhea-predominant Irritable Bowel Syndrome
NCT05593367 · Diarrhea-predominant Irritable Bowel Syndrome
NCT05369884 · Non-erosive Reflux Disease, Diarrhea-Predominant Irritable Bowel Syndrome
NCT04095988 · Diarrhea-predominant Irritable Bowel Syndrome
NCT01414244 · Diarrhea-Predominant Irritable Bowel Syndrome
Numakunai, Iwate
Aichi
Akita
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions